These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 31437170)

  • 1. Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis.
    Kwo PY; Puenpatom A; Zhang Z; Hui SL; Kelley AA; Muschi D
    PLoS One; 2019; 14(8):e0218759. PubMed ID: 31437170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained virologic response by direct-acting antivirals suppresses skeletal muscle loss in hepatitis C virus infection.
    Endo K; Sato T; Suzuki A; Yoshida Y; Kakisaka K; Miyasaka A; Takikawa Y
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1602-1609. PubMed ID: 31975438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience of a Portuguese Center: Effectiveness of Direct-Acting Antiviral Therapy for Hepatitis C.
    Falcão F; Lopes C; Viegas E; Perez R; Aldir I; Farinha H; Carvalho A; Mirco A; Marques S; Bana E Costa T; Miranda AC; Lebre L; Peixe P; Chagas C; Mansinho K; Correia JM
    Acta Med Port; 2019 Mar; 32(3):189-194. PubMed ID: 30946789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SUSTAINED VIROLOGIC RESPONSE RATE IN CHRONIC HEPATITIS C PATIENTS THROUGH DIRECT-ACTING ANTIVIRALS THERAPY.
    Torres AD; Sparvoli JMH; Sparvoli AC; Gonçalves CV
    Arq Gastroenterol; 2019; 56(4):394-398. PubMed ID: 31800735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
    Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
    Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
    Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P
    Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
    Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
    World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
    Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
    World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration.
    Fox DS; McGinnis JJ; Tonnu-Mihara IQ; McCombs JS
    J Gastroenterol Hepatol; 2017 Jun; 32(6):1136-1142. PubMed ID: 27869323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
    Bhamidimarri KR; Ladino M; Pedraza F; Guerra G; Mattiazzi A; Chen L; Ciancio G; Kupin W; Martin P; Burke G; Roth D
    Transpl Int; 2017 Sep; 30(9):865-873. PubMed ID: 28332729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders.
    Jiang X; Song HJ; Wang W; Henry L; Childs-Kean LM; Re VL; Park H
    J Manag Care Spec Pharm; 2021 Jul; 27(7):873-881. PubMed ID: 34185563
    [No Abstract]   [Full Text] [Related]  

  • 14. Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV).
    Walker DR; Pedrosa MC; Manthena SR; Patel N; Marx SE
    Adv Ther; 2015 Nov; 32(11):1117-27. PubMed ID: 26538232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C: How Good Are Real-Life Data and Do Generics Work.
    Tran AN; Lim JK
    Gastroenterol Clin North Am; 2020 Jun; 49(2):279-299. PubMed ID: 32389363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.
    Virlogeux V; Pradat P; Hartig-Lavie K; Bailly F; Maynard M; Ouziel G; Poinsot D; Lebossé F; Ecochard M; Radenne S; Benmakhlouf S; Koffi J; Lack P; Scholtes C; Uhres AC; Ducerf C; Mabrut JY; Rode A; Levrero M; Combet C; Merle P; Zoulim F
    Liver Int; 2017 Aug; 37(8):1122-1127. PubMed ID: 28423231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Success of the US Veterans Health Administration's Hepatitis C Virus Care Continuum in the Direct-acting Antiviral Era.
    Varley CD; Lowy E; Cartwright EJ; Morgan TR; Ross DB; Rozenberg-Ben-Dror K; Beste LA; Maier MM
    Clin Infect Dis; 2024 Jun; 78(6):1571-1579. PubMed ID: 38279939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection.
    Louie V; Latt NL; Gharibian D; Sahota A; Yanny BT; Mittal R; Bider-Canfield Z; Cheetham TC
    Perm J; 2017; 21():16-096. PubMed ID: 28368787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained virologic response with 6 weeks or less of direct-acting antiviral therapy for chronic hepatitis C: Experience at a veterans affairs healthcare system.
    Joshi P; Atherton A
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2173-2178. PubMed ID: 31062412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
    Conti F; Brillanti S; Buonfiglioli F; Vukotic R; Morelli MC; Lalanne C; Massari M; Foschi FG; Bernabucci V; Serio I; Prati GM; Negri E; Badia L; Caraceni P; Muratori P; Vitale G; Porro A; Morotti M; Mazzella G; Andreone P
    J Viral Hepat; 2017 Jun; 24(6):454-463. PubMed ID: 27976461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.